CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's various merger updates where amongst other things the company addressed several targeted merger candidates, the company is pleased to announce that it has finalized its bilateral negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).
Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company, founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor to HTDS. The company research and development dates back to 2005. The institute and the physical plant is located in Belgrade Serbia. The company has been completely self funding with private resources since its inception. Over the next several weeks Slavica management and its officers intend to provide a series of filings and updates on the company's efforts and progress in this field.
Under the agreement the medical team will receive payment in stock and options on HTDS security on a delivery and performance based schedule. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a vote of confidence in Slavica and who spearheaded the transaction, shall receive no stock in this transaction and in lieu will take stock options at a .03c strike price for up to 9% of the company common stock.
In other corporate news, the company representatives intend to visit mainland China for a second merger company discussions with a China based company in a similar field and research as Slavica with a significant operations already in place in China. Upon completion of the China merger, the company intends to name its new CEO, officers and directors consisting primarily of medical professionals and business consultants.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment